iPSC Cell Therapies

Biography

Andreas Scheel, as the EVP Head of Cell Therapy, leads the focus area “iPSC-based Cell Therapies” at Evotec. He also serves as the site head of the Cologne facility and is responsible for the cell therapy core teams located in Göttingen and Cologne.

In his role, Andreas is primarily responsible for the strategic development of this focus area together with a leadership team and for the establishment of strategic partnerships. He ensures the teams have the required expertise and fosters a cohesive identity across different sites. Andreas actively engages in internal networking and garners management support to promote transparency as this field continues to grow within the company. Additionally, he provides vital support to specific projects.

Andreas and his team's work holds immense importance, as they develop novel therapies to address urgent patient needs, striving to cure (rather than just treat) specific diseases with the unique advantages of iPSC-based cell therapy. At Evotec, Andreas values the company's commitment to investing in promising areas, granting senior leaders like himself the autonomy to define strategies. The dynamic and diverse environment at Evotec, with its vast expertise and multicultural teams, allows Andreas to excel in developing innovative platforms that have the potential to revolutionize medical treatments. His dedication and leadership position him as an invaluable asset in Evotec's pursuit of groundbreaking therapies.

Interest and Experience

Apart from his professional achievements, Andreas finds joy and fulfillment in his family and sports. He thrives in fast-paced environments and embraces challenging situations, making critical decisions with urgency, which allows him to tap into his creativity and excel in his work at Evotec.

Biography

Christine is a seasoned executive in the development, manufacturing and translation of Cell Therapies from early stage through clinical development until market reach in Europe. She joined Evotec International GmbH in 2021 as Executive Vice President, Head of Global Cell Therapy Translation & Medical Director. Recently she was appointed as Site Head of Evotec´s Cell Manufacturing site in Modena (IT). Her focus is the integrated development of cell therapy and the building of partnerships with Pharma/ Biotech.

Christine brings more than 30 years of experience in clinical and translational Cell Therapy, both in the allogeneic and autologous field, complemented by the iPSC-focus at Evotec. From 2008 to 2020 she served as CEO and Medical Director at Apceth, Cell & Gene therapy (Munich, GER, now Minaris Regenerative Medicine) building the Biotech from start-up to a profitable CDMO and research company. The company developed the worldwide first clinical study with genetically modified stem cells (MSC). Apceth was acquired by Hitachi Chemical in 2019 and integrated into a global CDMO network. Prior to that she served as Medical Director and Qualified Person at a non-profit organization for stem cell donation and cord blood transplantation.

Christine has a strong medical background as Senior Hematologist/ Oncologist working in academic Hospitals and the University Hospital in Munich with a focus on hematologic stem cell transplantation and adoptive cell therapy (1988-2002).

She holds a medical license from University of Munich and performed her PhD in experimental Hematology at the Helmholtz Society (Munich). She worked over 10 years as certified Qualified Person, and contributed in task forces and associations to the progress of Cell Therapy.